Explain this page
Arphra AIPlain-English read on Johnson & Johnson’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.28% | -3.10% | -1.89% | -10.33% | +8.50% | +7.70% | +43.43% | +42.00% | +34.11% | +94.68% | +18169.67% |
Aftermarket
LiveLast trade
$222.72
1 sh
Bid
$222.35
100 sh
Ask
$225.00
100 sh
Spread
$2.650
Sector & industry today
LiveSectors
- Basic Materials+0.98%
- Utilities+0.94%
- Energy+0.83%
- Consumer Cyclical+0.49%
- Industrials+0.25%
- Technology+0.21%
- Financial Services+0.05%
- Healthcare-0.26%
- Communication Services-0.39%
- Consumer Defensive-0.79%
- Real Estate-0.98%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-1.78%
- Coal-6.27%
- Information Technology Services+6.00%
- Hardware, Equipment & Parts+5.17%
- Computer Hardware-4.64%
- Staffing & Employment Services+4.08%
- Gambling, Resorts & Casinos+3.71%
- Broadcasting+3.70%
- Integrated Freight & Logistics+3.68%
- Agricultural - Machinery+3.64%
- Medical - Healthcare Information Services+3.36%
- Copper+2.99%
Fair value
Football field →Weighted blend
$284.23
+27.52% vs spot
Recommendation
Strong Buy
18 of 19 methods
Method spread
6bull12bear
±5% threshold
Analyst PT consensus: $249.27 (+11.84%)
Total assets
$199.21B
Total debt
$47.93B
Cash & equiv
$19.71B
Operating CF
$24.53B
Free cash flow
$19.7B
Buybacks
-$5.95B
Analyst view
DB · price_targets + analyst_gradesConsensus target
$249.27
+11.84% upside
Low
$208.00
Median
$250.00
High
$283.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Johnson & Johnson (JNJ) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 12, 2026
- Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategyzacks.com·May 12, 2026
- Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remissionprnewswire.com·May 07, 2026
- A $2 Million Portfolio Still Has a Safety Trap Most Investors Over 60 Miss247wallst.com·May 04, 2026
- CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysisprnewswire.com·May 04, 2026
- CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysisprnewswire.com·May 04, 2026
- J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicineyoutube.com·May 02, 2026
- Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfoliozacks.com·May 01, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $24.06B | $5.24B | $2.14 |
| Q4 Dec 2025 | $24.56B | $5.12B | $2.10 |
| Q3 Sep 2025 | $23.99B | $5.15B | $2.12 |
| Q2 Jun 2025 | $23.74B | $5.54B | $2.29 |
| Q1 Mar 2025 | $21.89B | $11B | $4.54 |
| Q4 Dec 2024 | $22.52B | $3.43B | $1.41 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Decker Robert J officer: VP Corporate Controller | Sell | 4,075 | $1.01M | Feb 27, 2026 |
Schmid Timothy officer: EVP, WW Chair, MedTech | Sell | 1,322 | $324.76K | Feb 20, 2026 |
Schmid Timothy officer: EVP, WW Chair, MedTech | Sell | 13,625 | $3.33M | Feb 18, 2026 |
Schmid Timothy officer: EVP, WW Chair, MedTech | Sell | 8,998 | $2.2M | Feb 18, 2026 |
REED JOHN C officer: EVP, Innovative Medicine, R&D | Sell | 2,283 | $554.77K | Feb 17, 2026 |
Wolk Joseph J officer: Exec VP, CFO | Sell | 24,961 | $6.06M | Feb 17, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $94.19B | $25.6B | $26.8B | $11.03 | +28.46% |
| FY 2024 | $88.82B | $22.15B | $14.07B | $5.79 | +15.84% |
| FY 2023 | $85.16B | $23.41B | $35.15B | $13.72 | +41.28% |
| FY 2023 | $79.99B | $21.01B | $17.94B | $6.73 | +22.43% |
| FY 2022 | $78.74B | $20.94B | $20.88B | $7.81 | +26.52% |